Literature DB >> 21354237

Conformational transition in the substrate binding domain of β-secretase exploited by NMA and its implication in inhibitor recognition: BACE1-myricetin a case study.

Sandipan Chakraborty1, Sanjay Kumar, Soumalee Basu.   

Abstract

BACE1 is a key protease involved in the proteolysis of amyloid precursor protein (APP) that generates a toxic peptide amyloid beta (Aβ), a pathological feature of Alzheimer's disease (AD). The enzyme is believed to possess an open and a closed conformation that corresponds to its free and inhibitor-bound form respectively. Here, we study the dynamic transition of BACE1 employing normal mode analysis (NMA) using a simplified elastic network model (ENM). Estimation of the catalytic cavity volume on the structures of BACE1 encoded by the lowest frequency normal mode reveals the dynamical transition of the enzyme from the open to the closed conformer. Detailed analysis reveals that concerted movement of different loop segments in the active site of the protein, namely flap regions, 10s loop, A loop and F loop, squeeze the catalytic cavity between the N-terminal and C-terminal lobe of the substrate binding domain of BACE1. We also propose that the NMA encoded multiple receptor conformations (MRC) of BACE1 elucidate the pharmacophoric feature necessary to inhibit the enzyme by a polyphenol, myricetin. van der Waals interaction is found to be the main driving force that guides the ligand induced conformational switching to the closed conformer. We suggest that NMA derived MRC of BACE1 is an efficient way to treat the receptor flexibility in docking and thus can be further applied in virtual screening and structure based drug design.
Copyright © 2011 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21354237     DOI: 10.1016/j.neuint.2011.02.021

Source DB:  PubMed          Journal:  Neurochem Int        ISSN: 0197-0186            Impact factor:   3.921


  7 in total

1.  α-Mangostin decreases β-amyloid peptides production via modulation of amyloidogenic pathway.

Authors:  Lan-Xue Zhao; Yan Wang; Ting Liu; Yan-Xia Wang; Hong-Zhuan Chen; Jian-Rong Xu; Yu Qiu
Journal:  CNS Neurosci Ther       Date:  2017-04-21       Impact factor: 5.243

2.  Structure-Activity Relationship Analysis of Flavonoids and Its Inhibitory Activity Against BACE1 Enzyme Toward a Better Therapy for Alzheimer's Disease.

Authors:  Nur Intan Saidaah Mohamed Yusof; Zafirah Liyana Abdullah; Norodiyah Othman; Fazlin Mohd Fauzi
Journal:  Front Chem       Date:  2022-06-27       Impact factor: 5.545

Review 3.  Polyphenols as therapeutic molecules in Alzheimer's disease through modulating amyloid pathways.

Authors:  Johant Lakey-Beitia; Ruben Berrocal; K S Rao; Armando A Durant
Journal:  Mol Neurobiol       Date:  2014-05-15       Impact factor: 5.590

4.  Hybrid approach to sieve out natural compounds against dual targets in Alzheimer's Disease.

Authors:  Sucharita Das; Sandipan Chakraborty; Soumalee Basu
Journal:  Sci Rep       Date:  2019-03-06       Impact factor: 4.379

5.  Application of computational methods for the design of BACE-1 inhibitors: validation of in silico modelling.

Authors:  Marek Bajda; Jakub Jończyk; Barbara Malawska; Sławomir Filipek
Journal:  Int J Mol Sci       Date:  2014-03-24       Impact factor: 5.923

6.  Changing Paradigm from one Target one Ligand Towards Multi-target Directed Ligand Design for Key Drug Targets of Alzheimer Disease: An Important Role of In Silico Methods in Multi-target Directed Ligands Design.

Authors:  Akhil Kumar; Ashish Tiwari; Ashok Sharma
Journal:  Curr Neuropharmacol       Date:  2018       Impact factor: 7.363

Review 7.  Molecular Level Insight Into the Benefit of Myricetin and Dihydromyricetin Uptake in Patients With Alzheimer's Diseases.

Authors:  Miaomiao Liu; Hong Guo; Zhongyuan Li; Chenghua Zhang; Xiaoping Zhang; Qinghua Cui; Jingzhen Tian
Journal:  Front Aging Neurosci       Date:  2020-10-23       Impact factor: 5.750

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.